F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Inclusion Criteria:

   - Biopsy proven prostate adenocarcinoma

   - Rising PSA after definitive therapy with prostatectomy or radiation therapy (external
   beam or brachytherapy)

      - Post radical prostatectomy (RP) - American Urological Association (AUA)
      recommendation

         - PSA greater than 0.2 ng/mL measured after at least 6 weeks from radical
         prostatectomy

         - Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA
         measurements greater than 0.2 ng/mL)

      - Post-radiation therapy - American Society for Radiation Oncology (ASTRO) -
      Phoenix consensus definition

         - A rise of PSA measurement of 2 or more ng/mL over the nadir

   - Able to provide written consent

   - Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG] /
   World Health Organization [WHO] equivalent)

Exclusion Criteria:

   - Unable to provide informed consent

   - Inability to lie still for the entire imaging time

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the Investigator, may significantly interfere
   with study compliance